Christine Siu, has been a member of our board of directors since December 2020. Ms. Siu is currently the Chief Executive Officer of BridgeBio Neuromuscular, a pharmaceutical company, and has held this role since January 2022. Previously, Ms. Siu served as the Chief Operating Officer in Residence of BridgeBio Pharma Inc., a pharmaceutical company, from January 2020 to January 2022, Chief Financial Officer of Eidos Therapeutics, Inc., a biopharmaceutical company from December 2017 to December 2019, Chief Operating Officer of Eidos Therapeutics, Inc. from April 2016 to December 2017, Chief Business Officer of The Bluefield Project to Cure Frontotemporal Dementia from 2014 to 2017, and as Senior Director of Corporate Development at Global Blood Therapeutics, Inc., a biopharmaceutical company, from 2012 to 2014. Ms. Siu also held positions at various private equity and venture capital firms, including Third Rock Ventures, LLC, Warburg Pincus LLC and Thomas, McNerney & Partners, LLC, where she invested in life sciences companies and served as a member of the board of directors of Bright Peak Therapeutics, Inc., a privately-held biotechnology company, from June 2021 to January 2025. Ms. Siu received an M.B.A. from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from the University of Michigan. We believe Ms. Siu is qualified to serve as a member of our Board of Directors because of her experience serving in various commercial roles in the life sciences industry.